← All companies

AIDX

20/20 Biolabs, Inc.

AIDX Nasdaq Services-Testing Laboratories EDGAR ↗

$0.43

+0.03 +6.45%

Key statistics

from XBRL data in SEC filings

Market cap

$4.52M

Revenue (TTM)

$2.05M

Net income (TTM)

-$3.74M

EPS (TTM)

$-0.76

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$4.22M

Total assets

$5.80M

Gross margin

29.6%

52-week range

$0.40 – $50.00

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement; Delisting notice or listing-rule failure Jul 22, 2026 8-K Regulation FD disclosure Jul 1, 2026 8-K Modified rights of security holders; Amended charter or bylaws May 26, 2026 10-Q Quarter ended 2026-03-31 May 20, 2026 8-K Results of operations (earnings release) May 20, 2026 8-K Entered a material agreement Apr 28, 2026 8-K Results of operations (earnings release) Apr 1, 2026 10-K Fiscal year ended 2025-12-31 Mar 31, 2026

Other filings

DEFA14A DEFINITIVE ADDITIONAL MATERIALS Jun 23, 2026 DEF 14A DEFINITIVE PROXY STATEMENT Jun 23, 2026 PRE 14A PRELIMINARY PROXY STATEMENT Jun 1, 2026 424B3 PROSPECTUS SUPPLEMENT May 21, 2026 424B3 PROSPECTUS SUPPLEMENT May 21, 2026 NT 10-Q NOTIFICATION OF LATE FILING May 15, 2026 424B3 PROSPECTUS SUPPLEMENT Apr 28, 2026 424B3 PROSPECTUS SUPPLEMENT Apr 28, 2026 424B3 PROSPECTUS Apr 13, 2026 424B3 PROSPECTUS Apr 13, 2026 EFFECT Apr 10, 2026 EFFECT Apr 9, 2026 CORRESP Apr 8, 2026 UPLOAD Apr 8, 2026 4 Apr 6, 2026 4 Apr 6, 2026 S-1 REGISTRATION STATEMENT Apr 6, 2026 POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 Apr 6, 2026 SCHEDULE 13G Mar 10, 2026 SCHEDULE 13D Mar 10, 2026 4 Mar 4, 2026 SCHEDULE 13G Feb 25, 2026 4 Feb 23, 2026 4 Feb 23, 2026 4 Feb 23, 2026 4 Feb 23, 2026 3 Feb 23, 2026 3 Feb 19, 2026 424B3 PROSPECTUS Feb 18, 2026 EFFECT Feb 17, 2026 3 Feb 17, 2026 3 Feb 17, 2026